Stephan von Haehling

Summary

Country: Germany

Publications

  1. pmc Inflammatory mediators in chronic heart failure: an overview
    Stefan D Anker
    Department of Clinical Cardiology, Imperial College School of Medicine, National Heart and Lung Institute, London, UK
    Heart 90:464-70. 2004
  2. ncbi Biomarkers for chronic heart failure
    Mitja Lainscak
    Division of Applied Cachexia Research, Department of Cardiology, Campus Virchow Clinic, Charite Universitatsmedizin Berlin, Berlin, Germany
    Heart Fail Monit 5:77-82. 2007
  3. ncbi Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Berlin, Germany
    J Am Coll Cardiol 50:1973-80. 2007
  4. pmc Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany Center for Cardiovascular Research CCR, Charite Medical School, Campus Mitte, Berlin, Germany
    Arch Med Sci 9:261-7. 2013
  5. doi Frailty and heart disease
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Campus Virchow Klinikum, Charite Medical School, Berlin, Germany Electronic address
    Int J Cardiol 168:1745-7. 2013
  6. pmc Iron deficiency in heart failure: a practical guide
    Nicole Ebner
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin 13353, Germany
    Nutrients 5:3730-9. 2013
  7. ncbi Muscle wasting in heart failure: An overview
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Int J Biochem Cell Biol 45:2257-65. 2013
  8. doi Recent developments in the treatment of heart failure: highlights from the American Heart Association's Scientific Sessions, Los Angeles, California, 3 - 7 December 2012
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, D 13353 Berlin, Germany
    Expert Opin Investig Drugs 22:933-7. 2013
  9. pmc Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain
    Stephan von Haehling
    Division of Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    CMAJ 185:E295-303. 2013
  10. doi Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    J Am Coll Cardiol 59:585-92. 2012

Detail Information

Publications99

  1. pmc Inflammatory mediators in chronic heart failure: an overview
    Stefan D Anker
    Department of Clinical Cardiology, Imperial College School of Medicine, National Heart and Lung Institute, London, UK
    Heart 90:464-70. 2004
  2. ncbi Biomarkers for chronic heart failure
    Mitja Lainscak
    Division of Applied Cachexia Research, Department of Cardiology, Campus Virchow Clinic, Charite Universitatsmedizin Berlin, Berlin, Germany
    Heart Fail Monit 5:77-82. 2007
    ..Lastly, we anticipate the potential of biomarkers in a variety of chronic diseases with similar pathophysiology...
  3. ncbi Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Berlin, Germany
    J Am Coll Cardiol 50:1973-80. 2007
    ..Our aim was assess the prognostic value of midregional pro-atrial natriuretic peptide (MR-proANP) using a new immunoassay in patients with chronic heart failure (HF)...
  4. pmc Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany Center for Cardiovascular Research CCR, Charite Medical School, Campus Mitte, Berlin, Germany
    Arch Med Sci 9:261-7. 2013
    ..Using the novel Nexfin Finapres technique, we sought to assess measures of cardiac performance in patients with cancer and compare these values with those from control subjects and patients with chronic HF...
  5. doi Frailty and heart disease
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Campus Virchow Klinikum, Charite Medical School, Berlin, Germany Electronic address
    Int J Cardiol 168:1745-7. 2013
    ..Screening for frailty in heart disease is important not only because of its prognostic value, but also because a variety of therapeutic interventions are available. ..
  6. pmc Iron deficiency in heart failure: a practical guide
    Nicole Ebner
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin 13353, Germany
    Nutrients 5:3730-9. 2013
    ....
  7. ncbi Muscle wasting in heart failure: An overview
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Int J Biochem Cell Biol 45:2257-65. 2013
    ..This article is part of a Directed Issue entitled: Molecular basis of muscle wasting. ..
  8. doi Recent developments in the treatment of heart failure: highlights from the American Heart Association's Scientific Sessions, Los Angeles, California, 3 - 7 December 2012
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, D 13353 Berlin, Germany
    Expert Opin Investig Drugs 22:933-7. 2013
    ..Other studies discussed here embraced the course of body wasting, particularly cachexia, and muscle wasting in patients with heart failure and the influence of eating behavior...
  9. pmc Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain
    Stephan von Haehling
    Division of Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    CMAJ 185:E295-303. 2013
    ..We assessed the value of PAPP-A for predicting short-term cardiovascular events in a large cohort of patients presenting with cardiac chest pain...
  10. doi Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    J Am Coll Cardiol 59:585-92. 2012
    ..This study sought to assess the effects of ursodeoxycholic acid (UDCA) on endothelial function and inflammatory markers in patients with chronic heart failure (CHF)...
  11. doi Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Int J Cardiol 162:27-32. 2012
    ..The aim is to investigate the prognostic value of copeptin with regard to mortality and morbidity in patients with symptomatic coronary artery disease (CAD)...
  12. doi Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Clin Sci (Lond) 123:601-10. 2012
    ..0001). MR-proANP may help in the prediction of all-cause death in patients with symptomatic CAD. Further studies should verify its prognostic value and confirm the appropriate cut-off value...
  13. doi Anemia in chronic heart failure: can we treat? What to treat?
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, 13353 Berlin, Germany
    Heart Fail Rev 17:203-10. 2012
    ..The RED-HF study will show whether use of darbepoetin alfa in anemic patients with chronic HF will reduce the combined endpoint of death for any reason or hospitalization for heart failure...
  14. doi Cardio-renal anemia syndrome
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Campus Virchow Klinikum, Charite Medical School, Berlin, Germany
    Contrib Nephrol 171:266-73. 2011
    ..In such patients, a steep increase in mortality rates has been observed. This article describes the suggested classification systems of CRAS, its clinical significance, and potential therapeutic avenues...
  15. ncbi The European Society of Cardiology working group on heart failure: Heart Failure Update 2003
    Stephan von Haehling
    Department of Clinical Cardiology, Imperial College School of Medicine, National Heart and Lung Institute, London, UK
    Heart Fail Monit 4:78-9. 2003
  16. ncbi Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure
    Stephan von Haehling
    Department of Clinical Cardiology, Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK
    Cardiovasc Res 73:298-309. 2007
    ..Finally, therapeutic approaches are discussed. These include dietary advice, ongoing studies, and future possibilities...
  17. ncbi Tumour necrosis factor-alpha and the failing heart--pathophysiology and therapeutic implications
    Stephan von Haehling
    Imperial College School of Medicine, National Heart and Lung Institute, Department of Clinical Cardiology, London, UK
    Basic Res Cardiol 99:18-28. 2004
    ..Nevertheless, TNFalpha antagonism remains a major target of CHF therapy, although counterbalancing this cytokine alone may not be sufficient...
  18. ncbi The relationship between age and production of tumour necrosis factor-alpha in healthy volunteers and patients with chronic heart failure
    Stephan von Haehling
    Department of Clinical Cardiology, National Heart and Lung Institute, London SW3 6LY, UK
    Int J Cardiol 90:197-204. 2003
    ..Elevated plasma levels of tumour necrosis factor-alpha (TNF-alpha) are present in patients with advanced chronic heart failure (CHF). However, the relationship between age and the immune response in CHF is unknown...
  19. doi Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charité Medical School Campus Virchow Klinikum, 13353 Berlin, Germany
    Eur J Heart Fail 12:484-91. 2010
    ..Adrenomedullin (ADM) is a vasodilatory peptide. Its plasma levels or its precursors have not been evaluated in large populations of patients with chronic heart failure (CHF). We sought to explore mid-regional proADM (MR-proADM)...
  20. doi Anemia in heart failure: an overview of current concepts
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Future Cardiol 7:119-29. 2011
    ..Finally, this article describes the potential costs incurred by treating anemic patients with heart failure...
  21. ncbi Statins and the role of nitric oxide in chronic heart failure
    Stephan von Haehling
    Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College, School of Medicine, London, UK
    Heart Fail Rev 8:99-106. 2003
    ..The doses needed to achieve the desired effects might be much lower than those needed to treat hypercholesterolemia...
  22. doi Statins for heart failure: still caught in no man's land?
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, D 13353 Berlin, Germany
    Clin Sci (Lond) 116:37-9. 2009
    ....
  23. ncbi Annual meeting of the American Heart Association. Dallas, Texas, USA, 13-16 November 2005
    Stephan von Haehling
    Imperial College School of Medicine, Department of Clinical Cardiology, National Heart and Lung Institute, London SW3 6LY, UK
    Expert Opin Investig Drugs 15:563-9. 2006
  24. ncbi Effect of noradrenaline and isoproterenol on lipopolysaccharide-induced tumor necrosis factor-alpha production in whole blood from patients with chronic heart failure and the role of beta-adrenergic receptors
    Stephan von Haehling
    Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
    Am J Cardiol 95:885-9. 2005
    ..This study demonstrated that noradrenaline and isoproterenol inhibit TNF-alpha production in patients with CHF in ex vivo whole blood in a dose-dependent fashion. The beta-blocker bisoprolol abolishes this effect...
  25. ncbi Future prospects of anticytokine therapy in chronic heart failure
    Stephan von Haehling
    Imperial College School of Medicine, Department of Clinical Cardiology, NationalHeart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK
    Expert Opin Investig Drugs 14:163-76. 2005
    ....
  26. ncbi Cachexia: a therapeutic approach beyond cytokine antagonism
    S von Haehling
    Department of Clinical Cardiology, National Heart and Lung Institute, Royal Brompton Hospital, London, UK
    Int J Cardiol 85:173-83. 2002
    ..The role of other approaches such as proteasome-inhibitors remains to be elucidated. Alternatively, interleukin-10 and other immunosuppressive cytokines may also be able to counterbalance certain features of cachexia...
  27. pmc Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure
    Stephan von Haehling
    Applied Cachexia Research, Dept of Cardiology, Charite Medical School, Campus Virchow Clinic, Berlin, Germany
    PLoS ONE 4:e6411. 2009
    ..Here we investigate whether a leukocyte redistribution occurs in CHF and whether this effect is influenced by beta-blocker therapy...
  28. ncbi Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders
    Stephan von Haehling
    Department of Cardiology, Applied Cachexia Research, Charite Medical School, Berlin, Germany
    Heart Fail Clin 5:549-60. 2009
    ..In addition to these acute phase reactants, several adhesion molecules, and lipopolysaccharide-signaling pathways are discussed...
  29. ncbi Cardiac cachexia: a systematic overview
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Pharmacol Ther 121:227-52. 2009
    ..Other drug classes of interest comprise angiotensin-converting enzyme inhibitors, beta-blockers, anabolic steroids, beta-adrenergic agonists, anti-inflammatory substances, statins, thalidomide, proteasome inhibitors, and pentoxifylline...
  30. doi Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study
    Stephan von Haehling
    Department of Cardiology, Applied Cachexia Research, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Eur J Heart Fail 13:656-63. 2011
    ..In addition, we sought to study the effects of nebivolol on the development of anaemia...
  31. doi Anaemia is an independent predictor of death in patients hospitalized for acute heart failure
    Stephan von Haehling
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    Clin Res Cardiol 99:107-13. 2010
    ..Acute heart failure is associated with a poor prognosis. It is important to identify patients at increased risk of adverse events. The presence of anaemia could help in this regard...
  32. ncbi Cellular endotoxin desensitization in patients with severe chronic heart failure
    Rakesh Sharma
    Clinical Cardiology, NHLI, Imperial College School of Medicine, London, UK
    Eur J Heart Fail 7:865-8. 2005
    ..It is not known if LPS desensitization occurs in CHF...
  33. doi Assessment of serum cotinine in patients with chronic heart failure: self-reported versus objective smoking behaviour
    Nicole Ebner
    Department of Cardiology, Applied Cachexia Research, Charite Medical School, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
    Clin Res Cardiol 102:95-101. 2013
    ..The value of self-reported smoking behaviour has not been validated in patients with HF. We sought to assess serum cotinine levels, a marker of recent tobacco exposure, in a cohort of clinically stable patients with chronic HF...
  34. doi Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock
    Joerg C Schefold
    Department of Nephrology and Intensive Care Medicine, Charite University Medicine, Campus Virchow, Berlin, Germany
    Scand J Infect Dis 42:164-71. 2010
    ..005, r = -0.28) in the overall samples group. Thus, GM-CSF therapy is associated with decreased IDO activity and reduced kynurenine pathway catabolites in sepsis. This may be due to an improved antibacterial defence...
  35. ncbi Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival
    Sabine Genth-Zotz
    Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
    Int J Cardiol 96:397-401. 2004
    ..We hypothesised that circulating Hsp70 levels are elevated in patients with CHF, more so in cachechtic patients, and that Hsp70 levels would relate to mortality...
  36. ncbi Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins
    Rakesh Sharma
    Clinical Cardiology, NHLI, Imperial College School of Medicine, Dovehouse Street, SW3 6LY, London, UK
    Eur J Heart Fail 7:479-84. 2005
    ..We sought to investigate the relationship between whole blood endotoxin responsiveness and serum lipoprotein concentrations. It is not known if low-dose LPS is sufficient to stimulate immune activation...
  37. doi Mechanism and novel therapeutic approaches to wasting in chronic disease
    Nicole Ebner
    Applied Cachexia Research, Department of Cardiology, Charite University, Medical School, Campus Virchow Klinikum, Berlin, Germany
    Maturitas 75:199-206. 2013
    ..We discuss therapeutic targets and such potential modulators as appetite stimulants, selective androgen receptor modulators, amino acids and naturally occurring peptide hormones...
  38. ncbi Cardiac cachexia is associated with right ventricular failure and liver dysfunction
    Miroslava Valentová
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany 1st Department of Internal Medicine, Faculty Hospital, Bratislava, Slovak Republic Electronic address
    Int J Cardiol 169:219-24. 2013
    ..The mechanisms involved in cardiac cachexia remain poorly understood. We examined the association of right ventricular (RV) and hepatic dysfunction with cardiac cachexia...
  39. ncbi Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure
    Aidan P Bolger
    Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
    Am J Cardiol 90:384-9. 2002
    ..IL-10 is, therefore, a potential therapy for use in chronic HF associated with inflammatory immune activation...
  40. doi Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke
    Wolfram Doehner
    Center for Stroke Research Berlin, Charite Universitatsmedizin Berlin, Germany
    J Am Coll Cardiol 60:346-54. 2012
    ..The purpose of this study was to investigate neuropeptides in patients presenting with symptoms of acute cerebrovascular disease...
  41. ncbi The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failure
    Sabine Genth-Zotz
    Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
    Eur J Heart Fail 8:366-72. 2006
    ..Plasma LPS activity is elevated in patients with severe chronic heart failure (CHF). An anti-CD14 antibody, IC14, blocks TNF production in healthy volunteers. It is not known whether IC14 prevents TNF production in CHF patients...
  42. doi Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure
    Anja Sandek
    Dept of Cardiology, Charite Universitatsmedizin, Berlin, Germany
    Int J Cardiol 157:80-5. 2012
    ..Small intestinal function may be altered in decompensated chronic heart failure (CHF) and translocating LPS may contribute to systemic inflammation observed in CHF...
  43. ncbi Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure
    Sabine Genth-Zotz
    Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
    Am J Cardiol 90:1226-30. 2002
    ..These results suggest that elevated plasma endotoxin activity observed in patients with HF is of pathophysiologic relevance...
  44. ncbi Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure
    Gabor Foldes
    Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
    Int J Cardiol 124:80-5. 2008
    ..Innate immune activation mediated by myocardial Toll-like receptors (TLRs) is involved in cardiovascular disease. The function and role of TLRs on peripheral leukocytes in human chronic heart failure (CHF) are not known...
  45. ncbi Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia
    Sandra Palus
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Berlin, Germany Center for Cardiovascular Research, Charite Medical School, Berlin, Germany
    Int J Cardiol 168:3412-8. 2013
    ..Recently, several groups have described a form of cardiomyopathy in CC animal models. Hence, we investigated the effect of simvastatin with its known anti-inflammatory and cardioprotective effects in a rat model of CC...
  46. doi Exercise capacity and body composition in living-donor renal transplant recipients over time
    Dirk Habedank
    Department Cardiology, Applied Cachexia Research, Charite Campus Virchow Klinikum, Berlin, Germany
    Nephrol Dial Transplant 24:3854-60. 2009
    ..Renal transplantation (RTx) restitutes the function of the failing organ and induces convalescence of the entire organism. Our study investigates whether this is accompanied by improvements in cardiovascular function and structural changes...
  47. ncbi A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a
    Joerg C Schefold
    Department of Nephrology and Intensive Care Medicine, University Medicine Berlin, Charite Campus Virchow Clinic, Berlin, Germany
    Shock 28:418-25. 2007
    ..This novel strategy might open a new therapeutic avenue for an interventional extracorporeal treatment of patients with sepsis...
  48. ncbi Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF)
    Susann Fülster
    Department of Cardiology, Applied Cachexia Research, Charite Medical School, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
    Eur Heart J 34:512-9. 2013
    ..To assess the prevalence and clinical impact of reductions in the skeletal muscle mass of patients with chronic heart failure (HF). Chronic HF is accompanied by co-morbidities that influence the quality of life and outcomes...
  49. doi Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure
    Tibor Szabo
    Applied Cachexia Research, Department of Cardiology, Campus Virchow Klinikum, Charite University Medical School, Berlin, Germany
    Int J Cardiol 147:47-51. 2011
    ..Their value and discriminatory power in comparison to dynamic range assessment of Si by minimal modelling are not well established...
  50. doi The emerging role of the gut in chronic heart failure
    Anja Sandek
    Applied Cachexia Research, Department of Cardiology, Campus Virchow Klinikum, Charite, Berlin, Germany
    Curr Opin Clin Nutr Metab Care 11:632-9. 2008
    ..Circulating cytokines act as cardiosuppressors. Their plasma levels predict increased mortality in chronic heart failure...
  51. doi The relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure
    Amalia Vaz Pérez
    Competence Network Heart Failure, Department of Cardiology, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Berlin, Germany
    Int J Cardiol 141:39-43. 2010
    ..Brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) are thought to reflect cardiac functional and structural damage...
  52. ncbi The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy
    Jochen Springer
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Berlin, Germany Center for Cardiovascular Research, Charite Medical School, Berlin, Germany Norwich Medical School, University of East Anglia, Norwich, UK Electronic address
    Int J Cardiol 168:3527-31. 2013
    ..Xanthine oxidase (XO) metabolizes purines to uric acid and its inhibition has been shown to improve clinical outcome in patients with chronic heart failure...
  53. ncbi Increased catabolic activity in adipose tissue of patients with chronic heart failure
    Tibor Szabo
    Charite University Medicine, Campus Virchow Klinikum, Department of Cardiology, Applied Cachexia Research, Berlin, Germany
    Eur J Heart Fail 15:1131-7. 2013
    ..We tested the hypothesis that increased plasma ANP levels are associated with an increased catabolic (lipolytic) state of white AT in patients with CHF...
  54. doi Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study
    Wolfram Doehner
    Center for Stroke Research Berlin, Charite Universitatsmedizin Berlin, Germany
    Int J Cardiol 161:137-42. 2012
    ..We aimed to test the ancillary metabolic effect of irbesartan on insulin sensitivity in patients with CHF...
  55. doi Role of iron deficiency and anemia in cardio-renal syndromes
    Philipp Attanasio
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Semin Nephrol 32:57-62. 2012
    ..This article summarizes studies investigating the influence of iron deficiency with or without anemia in chronic kidney disease and CHF and gives an overview of preparations of intravenous iron currently available...
  56. ncbi Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow
    Wolfram Doehner
    Division of Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Eur Heart J 28:821-8. 2007
    ....
  57. ncbi The gut and intestinal bacteria in chronic heart failure
    Anja Sandek
    Applied Cachexia Research, Department of Cardiology, Campus Virchow Klinikum, Charite Medical School, Augustenburger Platz 1, 13353 Berlin, Germany
    Curr Drug Metab 10:22-8. 2009
    ..Therefore, the gut poses an interesting target for therapeutic interventions in patients with CHF...
  58. ncbi Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review
    Wolfram Doehner
    Center for Stroke Research Berlin, Charite, Berlin, Germany
    Wien Klin Wochenschr 121:293-6. 2009
    ..Retrospective and epidemiological data for their beneficial effect in chronic obstructive pulmonary disease begin to accumulate and new fields (e.g. cancer and stroke) could be pending in the future...
  59. ncbi Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure
    Wolfram Doehner
    Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College, London, United Kingdom
    J Am Coll Cardiol 46:1019-26. 2005
    ..The aim of this study was to determine the significance of insulin resistance as an independent risk factor for impaired prognosis in patients with chronic heart failure (CHF)...
  60. ncbi Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers
    Mitja Lainscak
    Department of Cardiology, Division of Applied Cachexia Research, Campus Virchow Clinic, Charite Universitatsmedizin Berlin, Germany
    Int J Cardiol 132:303-11. 2009
    ..Finally, we speculate about the potential of sharing the biomarkers over a variety of chronic diseases with similar pathophysiology...
  61. doi Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial
    Stefan D Anker
    Applied Cachexia Research, Department of Cardiology, Charite Campus Virchow Klinikum, Berlin, Germany
    Eur Heart J 30:1331-9. 2009
    ..The prevalence, incidence, and prognostic value of anaemia in patients with an acute myocardial infarction (AMI) complicated by heart failure is unclear...
  62. doi Resting energy expenditure and the effects of muscle wasting in patients with chronic heart failure: results from the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF)
    Matthias Tacke
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    J Am Med Dir Assoc 14:837-41. 2013
    ..Glucagonlike peptide 1 (GLP-1) is linked to REE in healthy individuals. We aimed to evaluate (1) whether REE is elevated in patients with HF with muscle wasting, and (2) whether basal GLP-1 levels are linked to REE in HF...
  63. doi Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke
    Nadja Scherbakov
    Center for Stroke Research Berlin, Charite Universitatsmedizin Berlin, Berlin, Germany
    Cerebrovasc Dis 33:37-46. 2012
    ..Increased levels of ADMA have been found in chronic heart failure (CHF). We hypothesized that peripheral ED in acute ischemic stroke is associated with increased ADMA levels...
  64. ncbi Altered intestinal function in patients with chronic heart failure
    Anja Sandek
    Department of Gastroenterology, Charite, Campus Mitte, Berlin, Germany
    J Am Coll Cardiol 50:1561-9. 2007
    ..We evaluated morphology and function of the gut in patients with chronic heart failure (CHF)...
  65. doi Nutrition in heart failure: an update
    Anja Sandek
    Applied Cachexia Research, Department of Cardiology, Charite Medical School, Berlin, Germany
    Curr Opin Clin Nutr Metab Care 12:384-91. 2009
    ..Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia...
  66. doi The cholesterol paradox revisited: heart failure, systemic inflammation, and beyond
    Stephan von Haehling
    Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Heart Fail Clin 4:141-51. 2008
    ..Also discussed is the potential of statins, which might be able to exert beneficial effects in both clinical conditions, despite lowering plasma cholesterol values...
  67. pmc Changes in serum creatinine in the first 24 hours after cardiac arrest indicate prognosis: an observational cohort study
    Dietrich Hasper
    Department of Nephrology and Medical Intensive Care, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    Crit Care 13:R168. 2009
    ....
  68. doi Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms
    Jörg C Schefold
    Department of Nephrology and Intensive Care, Charite University Medicine, Campus Virchow Clinic, Berlin, Germany
    Nephrol Dial Transplant 24:1901-8. 2009
    ..Here we investigate Trp catabolism, IDO activity and the role of inflammation in moderate to very severe CKD and haemodialysis...
  69. doi Absolute and functional iron deficiency in professional athletes during training and recovery
    Simon Reinke
    Division of Applied Cachexia Research, Department of Cardiology, Charite Universitatsmedizin Berlin, Germany
    Int J Cardiol 156:186-91. 2012
    ..We hypothesised that physical extremes result in ID in elite athletes and that the short recovery period may be insufficient to allow a lasting replenishment of iron reserves...
  70. doi Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia
    Jochen Springer
    Department of Cardiology, Applied Cachexia Research, Charite Medical School, Berlin, Germany
    Int J Cancer 131:2187-96. 2012
    ..Food intake and spontaneous locomotor activity were higher, indicating a higher quality of life. Inhibition of XO can reduce tissue wasting and improve survival in cancer cachexia and clearly clinical studies are needed...
  71. doi Risk stratification in patients with chronic heart failure based on metabolic-immunological, functional and haemodynamic parameters
    Ralph Herrmann
    Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Int J Cardiol 156:62-8. 2012
    ..A vast array of parameters has been proposed to predict mortality in chronic heart failure (CHF). Their applicability into clinical practice remains challenging due to economical and availability considerations...
  72. doi Biomarkers for chronic heart failure : diagnostic, prognostic, and therapeutic challenges
    Mitja Lainscak
    Division of Applied Cachexia Research, Department of Cardiology, Campus Virchow Clinic, Charite Universitatsmedizin, Berlin, Germany
    Herz 34:589-93. 2009
    ..The authors review some of those biomarkers and speculate on the possible roles of combining two or more of them...
  73. ncbi Systemic changes of tryptophan catabolites via the indoleamine-2,3-dioxygenase pathway in primary cervical cancer
    Christina Fotopoulou
    Department of Gynecology and Obstetrics, Charite, Virchow Campus Clinic University Hospital, Augustenburger Platz 1, 13353 Berlin, Germany
    Anticancer Res 31:2629-35. 2011
    ..Kynurenines are involved in various diseases such as renal failure, sepsis and cancer. We aimed to investigate whether systemic levels of kynurenines are induced in primary cervical cancer (PCC)...
  74. ncbi The American Heart Association's Scientific Sessions 2006. Chicago, IL, November 12-15, 2006
    Stephan von Haehling
    Department of Clinical Cardiology, Imperial College School of Medicine, National Heart and Lung Institute, London, UK
    Heart Fail Monit 5:101-3. 2007
  75. ncbi Hormonal consequences and prognosis of chronic heart failure
    Philipp Attanasio
    Department of Cardiology, Charite Medical School, Campus Virchow Klinikum, Berlin, Germany
    Curr Opin Endocrinol Diabetes Obes 18:224-30. 2011
    ..This review aims to highlight players of the catabolic-anabolic imbalance, regulators or appetite, and other mediators that are involved in the progression of CHF to cachexia...
  76. doi The influence of age and sex on disease development in a novel animal model of cardiac cachexia
    Sandra Palus
    Center for Cardiovascular Research, Charite, Campus Mitte, Berlin, Germany
    Int J Cardiol 133:388-93. 2009
    ..These models define cachexia only as a reduction in weight gain rather than weight loss. In this pilot study, we aimed to establish a model of genuine weight loss following chronic heart failure...
  77. doi Overview of emerging pharmacotherapy in chronic heart failure
    Tibor Szabo
    Charite Medical School, Campus Virchow Klinikum, Applied Cachexia Research, Department of Cardiology, Augustenburger Platz 1, 13353 Berlin, Germany
    Expert Opin Pharmacother 10:2055-74. 2009
    ..This review will focus on recent developments and potential future candidates of pharmacological CHF therapy...
  78. doi Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference
    Thomas Kung
    Applied Cachexia Research, Charite Medical School, Department of Cardiology, Campus Virchow Klinikum, Augustenburger Platz 1, D 13353 Berlin, Germany
    Expert Opin Investig Drugs 19:579-85. 2010
    ..Novel therapeutic approaches shown here include melanocortin-4 receptor antagonists, myostatin inhibition, beta-blockers, IL-6 antagonism synthetic ghrelin and vitamin D...
  79. ncbi Statins: a treatment option for chronic heart failure?
    Stephan von Haehling
    National Heart and Lung Institute, Department of Clinical Cardiology, Imperial College School of Medicine, London, UK
    Heart Fail Monit 4:90-7. 2004
    ..It is therefore tempting to speculate that low doses of statins still confer pleiotropic effects without lowering plasma cholesterol levels...
  80. ncbi Interleukin-6 serum level assessment using a new qualitative point-of-care test in sepsis: A comparison with ELISA measurements
    Joerg C Schefold
    Department of Nephrology and Intensive Care, Charite University Medicine, Campus Virchow Clinic, Berlin, Germany
    Clin Biochem 41:893-8. 2008
    ..We investigated whether IL-6 can be assessed using a new densitometric point-of-care (POC) bedside assay...
  81. ncbi The European Society of Cardiology (ESC) Annual Meeting 2005
    Stephan von Haehling
    Imperial College School of Medicine, National Heart and Lung Institute, London, UK
    Heart Fail Monit 4:150-2. 2005
  82. ncbi The need for a standardized definition for cachexia in chronic illness
    Jochen Springer
    Animal Research Unit, Division of Applied Cachexia Research, Charite, Campus Virchow Klinikum, Berlin, Germany
    Nat Clin Pract Endocrinol Metab 2:416-7. 2006
  83. ncbi Pleiotropic effects of angiotensin-converting enzyme inhibitors and the future of cachexia therapy
    Stephan von Haehling
    J Am Geriatr Soc 53:2030-1. 2005
  84. ncbi Activation of the NF-kappaB system in peripheral blood leukocytes from patients with chronic heart failure
    Ewa A Jankowska
    Cardiology Department, Military Hospital, ul Weigla 5, 50 981 Wroclaw, Poland
    Eur J Heart Fail 7:984-90. 2005
    ..In vitro experiments were used to elucidate the role of lipopolysaccharide (LPS) as a stimulus for the NF-kappaB system in PBL...
  85. ncbi The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure
    Klaus K A Witte
    Department of Academic Cardiology, Castle Hill Hospital, Castle Road, Cottingham, Hull HU16 5JQ, UK
    Eur Heart J 26:2238-44. 2005
    ..Therefore, we examined the influence of long-term multiple micronutrient supplementation on left ventricular (LV) function, levels of pro-inflammatory cytokines, and quality-of-life (QoL) in elderly patients with CHF...
  86. ncbi Toll-like receptor modulation in cardiovascular disease: a target for intervention?
    Gabor Foldes
    Semmelweis University, 1st Department of Medicine, Budapest, Hungary
    Expert Opin Investig Drugs 15:857-71. 2006
    ..Their role as potential targets for therapeutic intervention is just beginning to be appreciated and this article reviews the current status of these treatment strategies for cardiovascular disease...
  87. ncbi beta-blockers in heart failure--much more than heart rate reduction
    Stephan von Haehling
    J Card Fail 8:379-80. 2002
  88. ncbi Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure
    Tibor Kempf
    Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
    J Am Coll Cardiol 50:1054-60. 2007
    ..We explored the prognostic utility of growth differentiation factor (GDF)-15 in patients with chronic heart failure (CHF)...
  89. ncbi Uric acid in CHF: marker or player in a metabolic disease?
    Wolfram Doehner
    Int J Cardiol 115:156-8. 2007
  90. ncbi Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?
    Stephan von Haehling
    Eur Heart J 28:2830-1. 2007
  91. doi Weight change with beta-blocker use: a side effect put into perspective
    Tibor Szabo
    Am J Med 121:e15; author reply e17. 2008
  92. doi Insulin resistance in chronic heart failure
    Wolfram Doehner
    J Am Coll Cardiol 52:239; author reply 239-40. 2008
  93. ncbi Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention
    Gerhard Paul Diller
    Am J Cardiol 94:1478-9; author reply 1479. 2004
  94. ncbi Impact of levosimendan treatment on chronic heart failure
    Stephan von Haehling
    Am J Cardiol 94:1105. 2004
  95. ncbi Uric acid as a prognostic marker in acute heart failure--new expectations from an old molecule
    Wolfram Doehner
    Eur J Heart Fail 9:437-9. 2007